deltatrials
Completed PHASE3 INTERVENTIONAL NCT00214721

A Study to Evaluate the Efficacy and Safety of an Experimental Solution for Peritoneal Dialysis

Sponsor: Baxter Healthcare Corporation

Conditions End Stage Renal Disease
Interventions Experimental Peritoneal Dialysis Solution
Updated 6 times since 2017 Last updated: Feb 26, 2025 Started: Feb 28, 2005 Completion: Jul 31, 2006
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00214721, this PHASE3 trial focuses on End Stage Renal Disease and remains completed. Sponsored by Baxter Healthcare Corporation, it has been updated 6 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshotCompleted~Apr 2025 – present · 17 months · monthly snapshotCompleted

Change History

6 versions recorded

  1. Apr 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Apr 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Feb 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Baxter Healthcare Corporation
  • Vantive Health LLC
Data source: Vantive Health LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations